COVID-19 Variants in Critically Ill Patients: A Comparison of the Delta and Omicron Variant Profiles.
COVID-19
COVID-19 variants
ICU
SARS-CoV-1
SARS-CoV-2
delta
disease severity
endothelial dysfunction
omicron
Journal
Infectious disease reports
ISSN: 2036-7430
Titre abrégé: Infect Dis Rep
Pays: Switzerland
ID NLM: 101537203
Informations de publication
Date de publication:
17 Jun 2022
17 Jun 2022
Historique:
received:
16
05
2022
revised:
14
06
2022
accepted:
15
06
2022
entrez:
23
6
2022
pubmed:
24
6
2022
medline:
24
6
2022
Statut:
epublish
Résumé
Coronavirus disease is a pandemic that has disrupted many human lives, threatening people's physical and mental health. Each pandemic wave struck in different ways, infectiveness-wise and mortality-wise. This investigation focuses on critically ill patients affected by the last two variants, Delta and Omicron, and aims to analyse if any difference exists between the two groups. intensive care unit (ICU) COVID-19 consecutive admissions between 1 October 2021 and 31 March 2022 were recorded daily, and data concerning the patients' demographics, variants, main comorbidities, ICU parameters on admission, and the outcome were analysed by a univariate procedure and by a multivariate analysis. 65 patients were enrolled, 31 (47.69%) belonging to the Omicron versus 34 (52.31%) to the Delta group. The mortality rate was 52.94% for the Omicron group versus 41.9% for the Delta group. A univariate analysis showed that the Omicron variant was associated with total comorbidities number, Charlson Comorbidity Index (CCI), pre-existing pulmonary disease, vaccination status, and acute kidney injury (AKI). In stepwise multivariate analysis, the total number of comorbidities was positively associated with the Omicron group, while pulmonary embolism was negatively correlated with the Omicron group. Omicron appears to have lost some of the hallmarks of the Delta variant, such as endothelialitis and more limited cellular tropism when it comes to the patients in the ICU. Further studies are encouraged to explore different therapeutic approaches to treat critical patients with COVID-19.
Sections du résumé
BACKGROUND
BACKGROUND
Coronavirus disease is a pandemic that has disrupted many human lives, threatening people's physical and mental health. Each pandemic wave struck in different ways, infectiveness-wise and mortality-wise. This investigation focuses on critically ill patients affected by the last two variants, Delta and Omicron, and aims to analyse if any difference exists between the two groups.
METHODS
METHODS
intensive care unit (ICU) COVID-19 consecutive admissions between 1 October 2021 and 31 March 2022 were recorded daily, and data concerning the patients' demographics, variants, main comorbidities, ICU parameters on admission, and the outcome were analysed by a univariate procedure and by a multivariate analysis.
RESULTS
RESULTS
65 patients were enrolled, 31 (47.69%) belonging to the Omicron versus 34 (52.31%) to the Delta group. The mortality rate was 52.94% for the Omicron group versus 41.9% for the Delta group. A univariate analysis showed that the Omicron variant was associated with total comorbidities number, Charlson Comorbidity Index (CCI), pre-existing pulmonary disease, vaccination status, and acute kidney injury (AKI). In stepwise multivariate analysis, the total number of comorbidities was positively associated with the Omicron group, while pulmonary embolism was negatively correlated with the Omicron group.
CONCLUSION
CONCLUSIONS
Omicron appears to have lost some of the hallmarks of the Delta variant, such as endothelialitis and more limited cellular tropism when it comes to the patients in the ICU. Further studies are encouraged to explore different therapeutic approaches to treat critical patients with COVID-19.
Identifiants
pubmed: 35735762
pii: idr14030052
doi: 10.3390/idr14030052
pmc: PMC9222818
doi:
Types de publication
Journal Article
Langues
eng
Pagination
492-500Références
N Engl J Med. 2020 Aug 6;383(6):590-592
pubmed: 32402155
BMJ. 2022 Mar 9;376:e069761
pubmed: 35264324
Arterioscler Thromb Vasc Biol. 2021 May 5;41(5):1774-1776
pubmed: 33792345
Arch Bronconeumol (Engl Ed). 2020 Nov;56(11):756-758
pubmed: 33994638
J Infect. 2020 Aug;81(2):e16-e25
pubmed: 32335169
Thromb Res. 2020 Dec;196:227-230
pubmed: 32916565
Nat Rev Nephrol. 2021 Nov;17(11):751-764
pubmed: 34226718
Influenza Other Respir Viruses. 2022 Apr 13;:
pubmed: 35415869
JAMA. 2022 Feb 8;327(6):583-584
pubmed: 34967859
Ann Intern Med. 2022 Jun;175(6):831-837
pubmed: 35286147
Int J Infect Dis. 2022 Mar;116:38-42
pubmed: 34971823
BMC Nephrol. 2021 Nov 1;22(1):359
pubmed: 34719384
Nat Rev Immunol. 2022 May;22(5):267-269
pubmed: 35414124
Lancet Infect Dis. 2022 Jul;22(7):959-966
pubmed: 35468332
Crit Care Nurs Q. 2022 Apr-Jun 01;45(2):108-118
pubmed: 35212651
Ann Intern Med. 2003 Apr 15;138(8):644-50
pubmed: 12693887
Eur Respir J. 2020 Jul 30;56(1):
pubmed: 32554538
J Am Med Dir Assoc. 2020 Nov;21(11):1546-1554.e3
pubmed: 33138936
Blood Purif. 2021;50(1):35-41
pubmed: 32615555
JAMA. 2022 Apr 5;327(13):1286-1288
pubmed: 35175280
BMJ Case Rep. 2021 Mar 22;14(3):
pubmed: 33753396
Children (Basel). 2022 Feb 12;9(2):
pubmed: 35204969
Am J Med Sci. 2022 Apr;363(4):281-287
pubmed: 35093394
Lancet. 2022 Jan 29;399(10323):437-446
pubmed: 35065011
Med (N Y). 2022 Apr 8;3(4):262-268.e4
pubmed: 35313451
Am J Respir Crit Care Med. 2022 May 10;:
pubmed: 35536284
Signal Transduct Target Ther. 2021 Dec 10;6(1):418
pubmed: 34893580
Vaccines (Basel). 2022 Feb 13;10(2):
pubmed: 35214741
Sci Rep. 2021 Jan 13;11(1):1137
pubmed: 33441892
Cell Res. 2022 Mar;32(3):319-321
pubmed: 35064226